Harrow, Inc. (NASDAQ:HROW) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lowered its position in Harrow, Inc. (NASDAQ:HROW - Free Report) by 89.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,138 shares of the company's stock after selling 99,446 shares during the quarter. Assenagon Asset Management S.A.'s holdings in Harrow were worth $323,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HROW. Vanguard Group Inc. raised its position in Harrow by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 1,872,100 shares of the company's stock valued at $62,809,000 after purchasing an additional 5,225 shares during the period. Braidwell LP raised its position in Harrow by 106.3% in the fourth quarter. Braidwell LP now owns 907,039 shares of the company's stock valued at $30,431,000 after purchasing an additional 467,401 shares during the period. D. E. Shaw & Co. Inc. raised its position in Harrow by 6.7% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 664,714 shares of the company's stock valued at $22,301,000 after purchasing an additional 41,896 shares during the period. Northern Trust Corp raised its position in Harrow by 7.5% in the fourth quarter. Northern Trust Corp now owns 319,084 shares of the company's stock valued at $10,705,000 after purchasing an additional 22,266 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in Harrow by 1.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 255,218 shares of the company's stock valued at $8,563,000 after purchasing an additional 3,589 shares during the period. Institutional investors and hedge funds own 72.76% of the company's stock.

Harrow Stock Up 1.1%

Shares of NASDAQ HROW traded up $0.34 during midday trading on Monday, reaching $31.00. 343,259 shares of the company's stock were exchanged, compared to its average volume of 496,779. Harrow, Inc. has a 52-week low of $20.36 and a 52-week high of $59.23. The stock has a market capitalization of $1.14 billion, a PE ratio of -55.36 and a beta of 0.40. The company has a debt-to-equity ratio of 2.01, a quick ratio of 0.85 and a current ratio of 0.91. The business's fifty day moving average price is $27.01 and its two-hundred day moving average price is $29.14.

Harrow (NASDAQ:HROW - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). The business had revenue of $47.83 million for the quarter, compared to analysts' expectations of $57.00 million. Harrow had a negative return on equity of 25.01% and a negative net margin of 10.19%. Analysts forecast that Harrow, Inc. will post -0.53 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on HROW shares. B. Riley cut their price objective on Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. BTIG Research started coverage on Harrow in a research report on Thursday, June 12th. They issued a "buy" rating and a $62.00 price objective on the stock. William Blair started coverage on Harrow in a research report on Tuesday, June 10th. They issued an "outperform" rating on the stock. Finally, HC Wainwright lifted their target price on Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a research report on Monday, May 12th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Harrow currently has a consensus rating of "Buy" and a consensus price target of $61.40.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.